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Introduction 
Cancer is one of the largest epidemics in our world. In 2012, an estimated 14 million new 
cases of cancer and 8.2 million cancer-related deaths were documented worldwide (National 
Cancer Institute, 2015). Cancer is also associated with aging; as life expectancy rises, so does the 
risk of getting cancer. Globally, an estimated one in three women and one in two men will 
develop cancer in their lifetimes (RT Answers, 2016). Cancer is characterized by uncontrollable 
cell growth that gains resistance to death signals, increasing pro-survival mechanisms of the 
cancerous cell and its properties (National Cancer Institute, 2015). Early detection and 
prevention of cancer has become just as paramount a concern as treatment, leading many to 
investigate new possible biomarkers for the disease. A viable biomarker is indicative of the 
presence of cancer within the body and helps diagnose patients promptly. Trefoil factors (TFFs) 
are proteins secreted by epithelial cells primarily for wound healing in mucosal membranes, 
which makes their investigation as biomarkers attractive (Thim & May, 2005).  
TFFs are secreted proteins that help in healing epithelial tissue in the stomach and thus 
have the potential to be biomarkers in many types of cancers (Thim & May, 2005). The normal 
function of TFFs is to regulate cell growth and assist cells in recognizing environmental stress 
that leads to inflammation (Aihara, Engevik, & Montrose, 2017). While TFFs are an intriguing 
cancer biomarker, further investigation of cancer cell function in the context of TFF expression 
could also provide information on the plausibility of TFFs as treatment targets. Such research is 
required to understand their expression and function in cancerous cells and therefore mitigate 
aggressive and potentially intractable metastatic disease.  
In this study, we aimed to identify the levels of TFF1 expression in cancerous cells that 
have not been investigated for this family of proteins. We then correlated the varying levels of 
1
Mosqueda-Banuelos and Pullen: Trefoil Factor 1 (TFF1) Expression in Breast Cancer
Published by Scholarship & Creative Works @ Digital UNC, 2018
TFF1 EXPRESSION IN MCF-7, E3, AND EWD8 BREAST CANCER CELL LINES  2 
 
expression to the aggressiveness of the cancer. We hypothesized that there would be varying 
amounts of TFF1 expression due to the functional characteristics of the cancer cells, and it was 
also our expectation that increased levels of TFF1 could possibly support a more aggressive 
cancer. Findings concluded that the breast cell lines tested were the only lines to express the 
protein and were actually less aggressive than the lines with no TFF1 expression.  
Literature Review 
Cancer markers are substances naturally produced by the body, and when cancer is 
present, these substances are produced at different levels (National Cancer Institute, 2015). As 
proteins secreted by epithelial cells primarily for wound healing in mucosal membranes, TFFs 
have the potential to be viable biomarkers (Thim & May, 2005).  These proteins have a trefoil 
motif structure composed of disulfide loops (Thim, 1989). There are three kinds of TFFs: TFF1, 
TFF2 and TFF3 (Aihara et al., 2017). TFF1, previously known as pS2, was first found in breast 
cancer, and TFF2 was extracted and purified from the pancreas (Masiakowski et al., 1982; 
Jørgensen, Jørgensen, Diamant, & Thim, 1982). Intestinal trefoil factor, now TFF3, was later 
found in both large and small intestines (Suemori, Lynch-Devaney & Podolsky, 1991). The 
proteins in this family are similar in structure but vary in expression and function throughout the 
body (Madsen, Nielsen, Tornøe, Thim, & Holmskov, 2007). 
The stomach is the only organ in which all three TFFs are expressed (Madsen et al., 
2007). TFF1 expression is highest in the stomach and colon, while TFF2 levels are highest in the 
stomach, and TFF3 levels are highest in the colon (Madsen et al., 2007). Other studies have 
looked at gastric and breast cancer to determine TFF expression (Lefebvre et al., 1996). TFF 
proteins are gaining recognition as cancer biomarkers in the field. The purpose of this literature 
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review is to investigate TFF expression in different cancers and identify their likelihood as 
biomarkers.  
Trefoil Factors in Gastric Cancer 
Gastric cancer is the fifth most common cancer worldwide, accounting for almost 1,000 
of the new cancer cases in 2012 (World Health Organization, 2015). There are known classic 
biomarkers for gastric cancer, but TFFs may be novel markers for the disease (Jin, Jiang, 
&Wang, 2015). TFF1 expression is essential for gastric mucosa cells to differentiate (Lefebvre et 
al., 1996). When expression of TFF1 is low, gastric adenomas can develop, and a percentage of 
the tumors can become cancerous (Lefebvre et al., 1996). Low expression of TFF1 in the gastric 
mucosa could show signs for early detection of stomach adenoma carcinoma, but the opposite 
could be true for TFF3. 
TFF3 expression levels are typically low in gastric mucosa but are overexpressed in 
gastric cancer (Chan et al., 2005). High TFF3 expression could be an effective biomarker for 
gastric cancer. In one study, 90 gastric cancer patients provided blood and urine samples that 
were examined for TFF3 levels (Xiao, Liu, Xiao, Ren, & Guleng, 2014). TFF3 levels were 
significantly higher in the serum and urine of cancer patients compared to the healthy 
individuals. These higher levels correlated with the advancement of the stages as well as the 
distance of metastasis. The authors concluded that TFF3 serum could be a biomarker for gastric 
cancer in detecting tumor stages and in identifying metastases. Overexpression of TFF3 in 
gastric cancer has led researchers to consider that it has potential as a cancer marker, and the 
same may be true for TFF2 (Cai et al., 2016). 
TFFs appear to be regulated on their own, but in some cases other proteins or substances 
help mediate their regulation. Sp3 protein was found to be an essential binding partner to TFF2, 
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which mediates the biological functions of the protein in gastric cancer cells (Cai et al., 2016). 
Knockdown of Sp3 protein prompted TFF2 upregulation and invasion of the gastric cancer cells. 
Overexpression of the two proteins suppressed cell proliferation, induced apoptosis of the cancer 
cells, and significantly lowered cell invasion. These findings showed that Sp3 is needed to 
regulate TFF2, and together, their overexpression (or their absence) could make useful cancer 
markers (Cai et al., 2016).   
Trefoil Factors in Breast Cancer 
According to the World Health Organization, breast cancer is the most common cancer 
among women and the second most common cancer worldwide (2015). It is well established that 
TFFs are expressed in MCF-7 breast cancer cell lines (Thim & May, 2005). In a study that used 
knockdown TFF1 in MCF-7 cells, the effects of estrogen with doxorubicin treatment were tested 
(Pelden, Insawang, Thuwajit, & Thuwajit, 2013). The cells that started with a low expression of 
TFF1 had upregulated expression after being transfected. The proteins expressed pro- or anti-
apoptotic properties, which led the authors to the idea that TFF1 has a role in the apoptotic status 
of the cells. The authors made connections that estrogen inhibits the actions of doxorubicin and 
that TFF1 can play a role in allowing estrogen to do this (Pelden et al., 2013). Kannan et al. used 
MCF-7 and T47D cells transfected with TFF3 to determine TFF function and relationship with 
estrogen (2010). TFF3 was identified as a novel growth factor in breast cancer, and its forced 
expression enhanced oncogenesis. Estrogen regulates TFFs and protects MCF-7 breast cancer 
cells from death. Together, estrogen and TFF expression can be a viable biomarker for breast 
cancer (Pelden et al., 2013; Kannan et al., 2010). 
 Ahmed, Griffiths, Tilby, Westley, and May investigated TFF3 expression in normal 
breast cancer cells, benign breast tumors, and in situ carcinomas (2012). In the normal breast 
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tissues, TFF3 protected the epithelial tissue, but its expression was lost in invasive breast 
cancers. TFF3 expression was also restricted at certain times during a woman’s menstrual cycle. 
It was found to have a negative relationship with tumor grade for the cancers studied but could 
better differentiate the type of tumor. The authors found that TFF3 stimulates angiogenesis in the 
cancer cells. The authors also stated that in vitro studies of this kind would help back up their 
claim that TFF3 may be a prognosis marker.  
May and Westley evaluated TFF3 as a biomarker and noted the response of this protein 
in breast cancer cells (May & Westley, 2015). Human TFF3 was transfected into breast cancer 
tissues from patients that underwent endocrine response therapy. Tumors with high TFF3 levels 
had evenly distributed expression compared to tumors with lower TFF3 levels, which had sparse 
expression. This pattern could be due to the amount of estrogen present in the body or the 
woman’s menstrual cycle, as stated previously (Ahmed et al., 2012). The authors concluded that 
TFF3 expression might work as an independent predictive biomarker for estrogen and be specific 
and sensitive as a marker in breast cancer. 
Trefoil Factors in Other Cancers 
 There are over 100 types of known cancers, and only a few forms of cancer have been 
studied for TFF expression (National Cancer Institute, 2015). Prostate cancer, endometrial 
adenocarcinoma (EAC), and lung adenocarcinoma have been investigated for TFF expression, 
including their possible roles as biomarkers for these specific cancers (Bougen et al., 2013). In 
prostate cancer, forced expression of TFF1 was shown to decrease E-cadherin (protein) 
expression leading to an increase of metastases and invasion of the cancer cells, both in vivo and 
in vitro. In vivo, the cells invaded and metastasized at an increased rate. The authors concluded 
that overexpression of TFF1 could be a biomarker for prostate cancer and determine tumor 
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metastasis or tumor burden. In this study, E-cadherin transcription was mediated by TFF1; 
however, it is unclear exactly how the TFF expression is mediated. Some studies indicate that 
estrogen or estrogen receptor (ER) may play different roles in mediating TFF expression 
(Bougen et al., 2013).  
Estrogen levels have been found to correlate with TFF levels in many breast cancer 
studies. Like in breast cancer, the combination of ER and TFF can make for a specific marker in 
uterine cancer (Mhawech-Fauceglia et al., 2013). In EAC, it has been confirmed that high levels 
of ER lead to good prognosis for the cancer (Mhawech-Fauceglia et al., 2013). Mhawech-
Fauceglia et al. aimed to evaluate TFF3 expression and prognosis as well as look at its 
relationship with ER (2013). High levels of TFF3 corresponded with those of ER, providing 
evidence that TFF3 and ER lead to better tumor outcomes. TFF3 could possibly stand alone as a 
biomarker for EAC patients, but additional investigation is needed to support this. The authors 
suggested further research of knockdown TFF3 in EAC to determine its role as a cancer marker 
and in proliferation, migration, and invasion of tumors (Mhawech-Fauceglia et al., 2013). 
Identified biomarkers for uterine cancer exist, but TFFs can be compared to these to analyze their 
effectiveness and expression. 
Lung cancer is the deadliest and most common cancer worldwide, which compels the 
need for biomarkers for early onset detection (Madsen et al., 2007).  Wang et al. studied the 
expression of established biomarkers TTF-1, CK7, P63, and CK5/6 in lung adenocarcinoma and 
squamous cell carcinoma and compared their expression patterns to those of TFF3 (2015). In 
comparison to the established markers, TFF3 had a 90% expression pattern in lung 
adenocarcinoma. The authors found higher levels of TFF3 in the cancer cells, which varied in the 
amount of expression between the cell lines, and TFF3 played a role in differentiating the cells. 
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Lastly, the authors concluded that TFF3 is all around “more sensitive” as a biomarker for all 
organs, not just specific organs compared to the established biomarkers (Wang et al., 2015). This 
study showed that TFF3 has the potential of being a biomarker when compared to established 
markers.  
Conclusion 
Cancer treatment has progressed, allowing researchers and physicians to get the five-year 
survival rate up to 66%, yet there is more that can be done to raise this percentage (Madsen et al., 
2007).  Earlier detection of the disease can lead to better prognosis and lower the amount of 
cancer-related deaths. TFF proteins have the potential to be biomarkers in many types of cancers. 
The expression levels of these proteins could identify various cases of early onset cancer or the 
amplitude of metastases. Many cancers still need to be investigated for TFF expression. We 
looked at breast cell lines MCF-7, E-3, EWD-8, skin A375, lung A549, colon COLO205, and 
mast cell lines P815 for TFF1 expression. We expected that varying levels of TFF1 expression 
would correlate with the functional characteristics of the cancer cells and that increased levels of 
TFF protein would support a more aggressive cancer. TFFs may be viable biomarkers that can 
aid in the early prognosis of cancer, which in turn may lead to the use of less invasive and 
detrimental forms of cancer treatment, and further investigation of these proteins as biomarkers 
is certainly necessary.   
Methods 
Cell Culture  
Breast (MCF-7, E3, and EWD8), skin (A549), lung (A375), colon (COLO205), and mast 
(P815) cells were cultured in 10cm diameter dishes and T75 cell culture flasks (VWR, Radnor, 
PA) in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher Scientific, Waltham, MA). 
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The culture medium was supplemented with (%volume) 10% equine and fetal bovine serum 
mixture (FBE from VWR), 2mM L-glutamine, 1mM sodium pyruvate, 0.01M HEPES, and 1 
unit/mL penicillin/streptomycin mixture (all from Thermo Fisher Scientific). Cells were 
enzymatically passaged with trypsin-EDTA (Thermo Fisher Scientific) once the bottom of the 
plate was fully covered by the cancerous cells. Since trypsin passaging can epigenetically 
influence cells over many passages, low passage number samples were used from liquid nitrogen 
storage. 
Protein Isolation and Concentration Measurements 
Approximately 3.5104 cells/ml from a passage were placed into each six-well plate and 
allowed to grow for 3 days. For cell lysis, the plate was put on ice and 100µl of 1X Lysis Buffer 
(Cell Signaling Technology, Danvers, MA) with protease inhibitors leupeptin and orthovanadate 
was added to each well. After lysis, the protein extract was centrifuged at 14,000xg for 10 
minutes to separate leftover cell/organelle membrane fractions from solubilized proteins. The 
supernatant, which contains intracellular proteins like TFFs, was kept to measure protein 
concentration. A Nanodrop 2000 device was used to measure protein concentrations from the 
samples.  
SDS-PAGE and Immunoblotting 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by 
immunoblotting was conducted on cell lysates and replicated to detect TFF expression in the 
cells. Equal quantities of total protein from each sample were loaded based on Nanodrop 
concentration data. The gel tank was set up using a 1X Tris-Glycine Running Buffer system. A 
size-standardized ladder and samples were loaded into 4%-20% polyacrylamide, Tris-Glycine 
gels and resolved according to manufacturer’s instructions (BIO-RAD, Hercules, CA). Once the 
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proteins separated, the gel was transferred to a stable nitrocellulose blot using BIO-RAD’s 
Transblot Electrode apparatus according to manufacturer’s protocol. Using Ponceau S, we 
observed equal loading in each blot. Next, a standard primary-blocking buffer of Tris-Buffered 
Saline, 0.1% (v/v) Tween-20 (TBS-T), 5% (v/v) bovine serum albumin was used to block non-
specific protein binding by incubating with the blots at ambient temperature for 1 hour with 
gentle agitation.  After blocking rabbit anti-human TFF1 (1:1000 dilution factor in block buffer; 
Cell Signaling Technology) was added to each blot, they were incubated overnight with gentle 
agitation at 4oC. On the following day, an anti-rabbit secondary antibody (1:5000 dilution; LI-
COR Biosciences, Lincoln, NE) solution of TBS-T, 5% (v/v) non-fat dry milk was added to the 
blot after removing the primary and rinsing with TBS-T. Blots were incubated with the 
secondary antibody solution for 1 hour at ambient temperature with gentle agitation.  Secondary 
incubation was followed by rinsing with TBS-T.  The secondary antibody has a horseradish 
peroxidase (HRP) enzyme attached to it; therefore, the blot was developed using a 
chemiluminescent HRP substrate detection reagent (WesternSure, LI-COR) and scanned with the 
LI-COR cDigit device.  
Migration Assay  
A scratch test was conducted to assess the migration of each cell line. Approximately 
5104 /ml of cells was added to a 10cm plate and allowed to settle and cover the plate. The cells 
were then scratched with a 200L pipette tip, and pictures were taken over time. Images were 
taken daily until the scratch completely closed. ImageJ (NIH, Bethesda, MD) was used to obtain 
the surface area of the scratch from each image.  
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Daily Count 
Daily counts for every cell line were also done to assess growth rate by adding 20µl of 
cells into each well of a six-well plate and counting one well per day. Trypsin was added to lift 
the cells and then counted with Life Technologies Countess II (Carlsbad, CA).    
Statistical Analysis 
A qualitative approach was taken to observe for the presence of bands indicating the 
presence of TFF1 among each cell line. Descriptive statistics were used to compare TFF1 
expression from cell type to cell type by taking the pixel density average of MCF-7 from the 
total of blots run (7) and using it to take a ratio for the other cell lines average expression. Using 
ImageJ, the surface area was averaged from each scratch for each cell line.  
 
Results 
After running Westerns blots, we found that only three of the seven cell lines tested expressed 
TFF1 (Fig. 1) Equal loading of the protein was assured through Ponceau S staining (Fig. 1). 
Breast MCF-7 was used as our positive control for TFF1 expression. Breast E3 and EWD8 cell 
lines also expressed the protein. On average, MCF-7 expressed the highest amount of TFF. Cell 
line E3 expressed the second highest amount of TFF, and EWD8 expressed the lowest amount, 
yet the ratio was much smaller than MCF-7 for these cell lines (Fig 2). From the scratch tests, 
MCF-7, E3, and EWD8 appear to migrate the slowest (Fig. 3). E3 on average took eight days to 
close the scratch; MCF-7 took an average of five days to seal the closure, and EWD8 averaged 
six days. Cell line A549, which did not express TFF1, on average closed the scratch in two days. 
Daily cell count for each cell type showed that MCF-7 and E3had lower proliferation rates 
compared to the cell lines that did not express TFF1. At the end of the six-day count, cell 
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concentration was 51,700 cells/mL for MCF-7, 39,400 for E3 cells/mL and 2,090,000 cells/mL 
for EWD8 (Fig. 4).  
 
 
 
 
Figure 1. TFF expression is shown through Western blot. MCF-7 expressed the most protein 
overall. Ponceau S staining of the blots was done to ensure equal loading among each cell line.  
 
 
Figure 2. Pixel density was taken from the blots. The values were averaged and a ratio was taken 
from the average of MCF-7 expression. E3 and EWD8 expressed TFF protein. 
 
 
 
 
MCF-7       E3          EWD8       A375         A549 P815 
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Figure 3. Cell migration over time is shown after scratch tests were performed. Three scratches 
were made in 10ml petri dishes after the cells had completely covered the surface for each cell 
line, except P815 because of their floating properties. ImageJ was used to obtain the remaining 
surface area of the scratches from each image. MCF-7, E3, and EWD8 appear to have migrated 
the slowest. 
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Figure 4. Daily count of each cell line was done by adding 20µl of cells into six-well plates and 
counting one well per day using the trypan blue exclusion method and a Life Technologies 
Countess II device. Cells that did not express TFF proliferated more than those that expressed it, 
such as MCF-7 and E3. 
 
Discussion 
Our results show that only three of the seven total cell lines tested had TFF1 protein 
expression, including the positive control. We predicted that there would be varying levels of 
TFF1 among the cell lines because of their morphological characteristics. All three of our breast 
cell lines (MCF-7, E3, and EWD8) expressed TFF1 protein; this may be due to their luminal 
breast cancer characteristics. TFFs are well-known for being expressed in MCF-7 breast cancer 
cell lines, and in general, MCF-7 expressed the highest amount of TFF1 (Thim & May, 2005). 
E3 expressed the second highest amount of TFF1, and EWD8 expressed the lowest amount. As 
previously stated, estrogen appears to mediate TFF expression (Mhawech-Fauceglia et al., 2013). 
MCF-7 and E3 express estrogen receptors, while EWD8 cell lines are estrogen-withdrawn cell 
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lines (Haughian et al., 2012). This may explain why MCF-7 and E3 expressed more TFF1 than 
the EWD8. EWD8 may be regenerating estrogen or have estrogen strands left over that would 
cause the low but present TFF1 expression (Haughian et al., 2012). Treating the cells with 
estrogen and progesterone is worth considering because it may significantly change the cell’s 
TFF expression. 
Previous research has found that overexpression of TFFs can be used as a possible 
biomarker for certain cancers. We also hypothesized that the cancer would be more aggressive if 
more TFF1 was present (i.e. faster growth rate, faster scratch closure), but our current 
observations showed the opposite pattern. Further assays suggested that these cells grow as 
slowly as the positive control (MCF-7) compared to the other cell lines, among which we did not 
detect any TFF1 expression. The cell lines expressing TFF1 generally took a longer time to close 
the scratch test. Daily counting provided more evidence that there were lower rates of 
proliferation on average in the breast cell lines. TFFs have been found to be biomarkers and to 
have oncogenic or tumor suppressing effects among many cancers. Some studies have correlated 
high TFF expression with aggressive cancers across different phenotypes, thus indicating 
promise as a cancer biomarker. There is also the possibility that TFFs are a side effect of the 
cancer, rather than direct oncogenes, yet further research is required.  
Our data suggested that the more TFF present, the less aggressive the cancer, suggesting 
its use as a possible target treatment for aggressive cancers. A next step would be to treat one of 
the more aggressive cell lines, like lung A549, with recombinant TFF and observe for any 
changes in the cancer’s aggressiveness. Since cell lines MCF-7, E3, and EWD8 expressed TFF1, 
we also plan to use gene-silencing techniques, such as siRNA transfection and/or CRISPR-Cas9, 
to edit the cells’ genomes and remove the TFF1 protein. We thus plan to observe what happens 
14
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to the aggressiveness of the cancer in the absence of the specific TFF in cell lines typically 
expressing the TFF. We would expect the treated lung A549 cell lines to become less aggressive 
and the knockdown-TFF1 cell lines MCF-7, E3, and EWD8 to become more aggressive.   
We originally predicted that TFF1 expression would be associated with more aggressive 
cancer cells, but we found the opposite pattern. The cancer cell lines that expressed TFF1 were 
less aggressive than those that did not, which implies that the loss of these proteins within these 
cancers would lead to a cancer that is more aggressive. While our results do not demonstrate 
what we initially hypothesized, it is important to note that TFFs may still be biomarkers for less 
aggressive cancer types. High expression levels of TFFs could allow for the detection of less 
aggressive or early stages of aggressive cancers. Based on these data and prospective clinical 
data, we would expect to see less aggressive breast cancers express higher levels of TFFs than 
more aggressive cancers. It continues to be debated whether TFFs are tumor suppressors or 
oncogenes and if varying levels of TFFs work as biomarkers in many cancers, yet the proteins 
seem to have the potential to be viable cancer biomarkers in less aggressive cancer settings, as 
shown from our findings.   
Identification of cancer biomarkers is essential to improving patient survival outcomes 
through the early detection of cancer. Treatment and therapy are crucial in the fight against 
cancer, but they often come with many discomforts. Biomarkers would allow for the early 
detection of cancer, which could possibly lead to less invasive and aggressive treatments. Further 
investigation would aid in the categorization of TFF1 in these cancers as oncogenic or tumor 
suppressors and would continue to reveal the possibility of TFF as a cancer treatment. 
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Future Directions 
Using the 4T1 breast mouse model, we tested for TFF expression and found that the cells 
do express TFFs (Fig 5.). The 4T1 mouse model is metastatic and can mimic the human immune 
system, making it the ideal model to study the effects of knockdown TFFs (Pulaski & Ostrand‐
Rosenberg, 2000). We aim to manipulate the cancer cell’s genome using the CRISPR-Cas9 
system to remove the expressed TFF in the 4T1 cell lines. CRISPR-Cas9 is a novel genetic 
engineering tool that grants the ability to disrupt or mutate genes within the cell (White & 
Khalili, 2016).  
We will attempt to target the TFF nucleotide sequence to inhibit transcription of TFF 
protein in the cancer cells and then observe for phenotypic changes in the cell lines once TFF has 
successfully been knocked down. We expect to see changes in aggression in terms of invasion 
and proliferation, and we plan on treating cell lines that have no TFF expression with 
recombinant TFFs and observing for changes in aggression (Fig. 6). Using transwell assays, we 
will conduct a migration assay by placing TFF or TFF-expressing cells at the bottom of the well 
and seeing if the cells migrate to the signal (Fig. 7).  Lastly, we will move to in vivo assays by 
injecting the knockdown TFF 4T1 cells into Balb/c mice, which will induce mammary tumors 
(Fig 8.). We plan to study how the metastasis of the tumors may or may not be mitigated by the 
absence of TFF expression.  
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Figure 5. We have assayed 4T1 cells for their TFF expression shown in the blot. These cells are 
a Balb/c mouse model of metastatic mammary adenocarcinoma. We will use these cells to 
observe the effects of TFF expression changes in vivo. 
 
 
  
 
 
 
 
 
 
Figure 6. It is predicted that knockdown TFF will cause the cells to decrease in aggression 
compared to cells treated with TFF, which may become more aggressive.   
TFF knockdown using CRISPR-
Cas9 in 4T1 cells. 
Observe for changes in 
aggressiveness of the cancer using 
migration, invasion and 
proliferation assays. 
- We predict cells will become less 
aggressive. 
Treat cells with no TFF expression 
with rTFF.  
Observe for changes in 
aggressiveness of the cancer using 
migration, invasion and 
proliferation assays. 
- We predict cells will become more 
aggressive. 
4T1 MCF-7 
T
F
F
1
  
17
Mosqueda-Banuelos and Pullen: Trefoil Factor 1 (TFF1) Expression in Breast Cancer
Published by Scholarship & Creative Works @ Digital UNC, 2018
TFF1 EXPRESSION IN MCF-7, E3, AND EWD8 BREAST CANCER CELL LINES  18 
 
 
Figure 7. Transwell invasion assays will be performed to test migratory potential of the cancer 
cells by adding TFF or cancer cells expressing TFF to the bottom of the wells.  
 
  
  
  
  
  
  
  
  
  
  
 
Figure 8. The 4T1 mouse model will be used to induce mammary tumors. 4T1 cell lines 
normally express TFFs; thus, by using knockdown cells, we will compare +/- endogenous TFFs 
regarding metastasis in vivo.  
  
Observe for changes in mammary 
tissue.  
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